On this week’s episode FirstWord Pharma PLUS editors Virginia Li and Simon King discuss an unexpected corporate re-manoeuvring around Biogen and Eisai’s controversial Alzheimer’s drug Aduhelm and disappointing clinical data for Sanofi’s breast cancer drug amcenestrant. Simon also catches up with FirstWord HealthTech’s executive editor Tina Tan to find out about some recent oncologist surveys looking at the use of digital technologies to help combat pandemic-extended treatment waiting times and the mental wellbeing of cancer patients.

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör FirstWord Pharma. Innehållet i podden är skapat av FirstWord Pharma och inte av, eller tillsammans med, Poddtoppen.